Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Consolidated Net Income (2021 - 2025)

Historic Consolidated Net Income for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$52.8 million.

  • Prime Medicine's Consolidated Net Income fell 59.79% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 896.7%. This contributed to the annual value of -$195.9 million for FY2024, which is 113.61% up from last year.
  • Prime Medicine's Consolidated Net Income amounted to -$52.8 million in Q3 2025, which was down 59.79% from -$52.6 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Consolidated Net Income ranged from a high of -$16.4 million in Q3 2021 and a low of -$65.6 million during Q4 2023
  • For the 5-year period, Prime Medicine's Consolidated Net Income averaged around -$44.3 million, with its median value being -$45.8 million (2024).
  • Data for Prime Medicine's Consolidated Net Income shows a peak YoY increase of 3754.39% (in 2022) and a maximum YoY decrease of 7883.26% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Prime Medicine's Consolidated Net Income stood at -$62.9 million in 2021, then skyrocketed by 37.54% to -$39.3 million in 2022, then plummeted by 67.1% to -$65.6 million in 2023, then soared by 35.6% to -$42.3 million in 2024, then dropped by 24.97% to -$52.8 million in 2025.
  • Its Consolidated Net Income was -$52.8 million in Q3 2025, compared to -$52.6 million in Q2 2025 and -$51.9 million in Q1 2025.